Prepartum immunotropic treatment shows promise for Holstein calves

A newly indexed Animals study suggests that immunotropic treatment of cows shortly before calving may improve how Holstein calves handle the first days of life. In the study, researchers assigned 60 pregnant cows to receive a single intramuscular dose of sodium nucleinate, a single dose of Ribotan, or saline 3 to 9 days before calving, then tracked the resulting calves through 60 days of age. The journal’s article page says calves from treated dams showed faster neonatal adaptation, higher body weights at 30 and 60 days, and bloodwork changes consistent with stronger protein and immune status. (mdpi.com)

The idea behind the work fits with what’s already known about the transition period. Late gestation is a metabolically and immunologically fragile window for dairy cows, and conditions during that period can influence colostrum quality, fetal development, immune transfer, and calf resilience after birth. Reviews in Animals and related calf-health literature have emphasized that prenatal and immediate postnatal factors interact to shape survival, growth, and immune competence, which helps explain why researchers are testing interventions aimed at the dam rather than the calf alone. (mdpi.com)

In this trial, the treatment protocol was straightforward: one 5 mL intramuscular injection of sodium nucleinate or Ribotan, compared with saline control. The calves were evaluated on days 1, 10, 30, and 60 for clinical, growth, hematologic, and biochemical measures. Based on the publisher’s summary, the treated groups had significantly greater body weight by days 30 and 60, with higher average daily gain, alongside increased total protein, albumin, and gamma-globulins. The same summary also notes faster standing and suckling behavior in newborn calves, suggesting a possible effect on immediate postnatal adaptation, not just later growth. (mdpi.com)

There’s also some background suggesting this paper builds on an existing line of regional research rather than appearing in isolation. Prior records indexed by FAO AGRIS describe earlier work on single prepartum sodium nucleinate administration in pregnant cows and its effects on newborn calf physiology, colostral immunity, and nonspecific resistance. Product listings for Ribotan describe it as an immunomodulator used in multiple species, including cattle, though those listings are commercial rather than regulatory or peer-reviewed evidence of efficacy in transition-cow programs. (agris.fao.org)

I didn’t find substantial independent expert reaction to this specific study, which likely reflects how early and niche the publication is. Still, the broader literature supports the biological plausibility that maternal immune and metabolic status before calving can alter calf outcomes. Other recent calf studies have shown that interventions affecting passive immunity, metabolic status, gut health, or inflammatory tone can influence early growth and resilience, even if the intervention itself differs from the immunotropic agents used here. That makes the findings interesting, but not yet practice-changing on their own. (mdpi.com)

Why it matters: For veterinary professionals, the study points to a familiar question with a less familiar tool: can better managing the dam’s immune status before calving improve calf performance after birth? If replicated, that could matter for dairies trying to reduce early-life setbacks, improve average daily gain, and tighten the connection between transition-cow management and calf outcomes. But there are important caveats. The study size was modest, follow-up appears limited to 60 days, and the tested products are not part of routine evidence-based protocols on most U.S. dairies. Established levers, including colostrum timing and quality, transition nutrition, environmental stress reduction, and disease prevention, still have the stronger evidence base and clearer implementation pathways. (mdpi.com)

There’s also a regulatory and market context to keep in mind. Immunomodulators exist in veterinary medicine, but product availability, approval status, and standard use patterns vary by country and product class. I did not find evidence that these specific products are widely positioned as standard prepartum dairy-cow tools in the U.S. market, which means any clinical interest here would likely start as a research and comparative-evidence conversation, not an immediate herd-health recommendation. (direct.aphis.usda.gov)

What to watch: The next meaningful step will be independent replication in larger commercial dairy settings, ideally with health-event, passive-transfer, and economic endpoints, plus clearer discussion of product regulatory status and practical fit within transition-cow protocols. (mdpi.com)